KCNN4
Intermediate conductance calcium-activated potassium channel protein 4
As of the edition of 20 October 2026, KCNN4 (intermediate conductance calcium-activated potassium channel protein 4, UniProt O15554) has 2 drugs tested at it and 3 companies on the list, 1 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- O15554
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 17
- Disease areas
- Blood and lymph; Inherited and neonatal; Immune system; Lungs and airways; Mental health; Chemically induced; Nervous system
- Registered trials of its drugs
- 12
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 1 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Senicapoc | Active | Phase 3 | none listed |
| Chlorzoxazone | Marketed | Phase 4 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Engaged | 1 |
| Undetermined | 1 |
| Total on the list | 3 |
| Company | Route |
|---|---|
| Icagen | Route A |
The other 2 companies at KCNN4
In the product3 companies in all; 2 are not named here, and no score is.
See the 3 companies at KCNN4, ranked, with the facts behind eachRequest access. Nothing is shown until you do.